Locally Advanced HER2 Positive Breast Carcinoma
2 clinical trials · Condition
◉ Watch Locally Advanced HER2 Positive Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (NCT05583110) | Spanish Breast Cancer Research Group | 2023-03-08 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (NCT05319873) | Jonsson Comprehensive Cancer Center | 2022-04-07 |
Track Locally Advanced HER2 Positive Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.